Difficulty: Intermediate | Prerequisites: Introductory neuroscience concepts (neurotransmitters, synaptic transmission), basic understanding of DSM diagnostic criteria for major depressive disorder.
This topic sits at the intersection of neuroscience and clinical psychology. It covers the full landscape of how depression is treated, from traditional medications through to newer pharmacological agents and brain-stimulation techniques. You need a working understanding of how neurotransmitters function at the synapse before this material will land properly. If you are shaky on serotonin, norepinephrine, and dopamine pathways, revisit those first. The reason this matters: depression is one of the most common and most treatment-resistant psychiatric conditions, and exam questions tend to focus on comparing mechanisms and explaining why certain treatments work faster or slower than others.
Depression has a strong genetic basis (69% concordance in identical twins) and is treated through pharmacological, neuromodulation, and psychotherapeutic approaches. Traditional antidepressants (MAOIs, TCAs, SSRIs, SNRIs) all work by increasing monoamine availability but differ in side-effect profiles and selectivity. Newer agents like ketamine and brexanolone offer rapid relief where older drugs take weeks, and neuromodulation therapies (ECT, TMS, DBS, VNS) target brain circuits directly, particularly in treatment-resistant cases.
Monoamine oxidase inhibitors (MAOIs)
Drugs that block the enzyme monoamine oxidase, preventing the breakdown of dopamine, norepinephrine, and serotonin in the synaptic cleft. Think of it as stopping the cleanup crew so neurotransmitters hang around longer.
Tricyclic antidepressants (TCAs)
An older class of antidepressant that blocks the reuptake of norepinephrine and serotonin, increasing their concentration in the synapse. In simple terms, they plug the recycling pump so more neurotransmitter stays available.
Selective serotonin reuptake inhibitors (SSRIs)
Drugs that specifically block the reuptake of serotonin only, raising its level in the synapse with fewer off-target effects than TCAs or MAOIs. Think of it as a more precise version of the same reuptake-blocking idea, narrowed down to one neurotransmitter.
Serotonin and norepinephrine reuptake inhibitors (SNRIs)
Antidepressants that block reuptake of both serotonin and norepinephrine, offering a dual-action approach. In simple terms, they are SSRIs with an added norepinephrine component.
Presynaptic autoreceptor desensitisation
The process by which autoreceptors on the presynaptic neuron become less responsive over time, allowing sustained increases in neurotransmitter release. This is why SSRIs and SNRIs take several weeks to produce therapeutic effects, even though they alter synaptic chemistry within hours.
Brexanolone
A recently approved treatment for postpartum depression that acts as an indirect agonist of the GABA-A receptor. In simple terms, it enhances the brain's main inhibitory system and works within about 60 hours.
Ketamine
An NMDA receptor antagonist that provides rapid relief in treatment-resistant depression. Think of it as a fast-acting antidepressant that works through an entirely different pathway (glutamate) than traditional drugs.
Electroconvulsive therapy (ECT)
A procedure that induces controlled seizures via electrical stimulation of the brain, used primarily for severe, treatment-resistant depression. In simple terms, a brief, controlled seizure appears to "reset" certain brain circuits, with a response rate above 50%.
Transcranial magnetic stimulation (TMS)
A non-invasive technique that applies magnetic pulses to the prefrontal cortex to alter neuronal activity. Think of it as a gentler, more targeted alternative to ECT, with fewer side effects but a lower response rate (under 30%).
Deep brain stimulation (DBS)
A surgical intervention that implants electrodes in specific brain regions (e.g. the subgenual anterior cingulate cortex) to modulate activity in treatment-resistant depression.
Vagus nerve stimulation (VNS)
Electrical stimulation of the vagus nerve, which indirectly affects brain activity through brainstem connections. Used in treatment-resistant cases where other approaches have not worked.
Neurogenesis
The growth of new neurons, particularly in the hippocampal dentate gyrus. Several antidepressant treatments promote neurogenesis, and the timeline of new neuron growth aligns with the weeks-long lag before antidepressants take effect.
Concordance rate
The probability that both members of a twin pair share a given trait. A high monozygotic concordance rate relative to the dizygotic rate signals a strong genetic contribution.
Affective disorders have a substantial heritable component
Close relatives of diagnosed individuals are 10 times more likely to develop an affective disorder
Monozygotic (identical) twin concordance: 69%
Dizygotic (fraternal) twin concordance: 13%
The large gap between monozygotic and dizygotic rates is strong evidence for genetic influence
Specific genes implicated include RORA and GRM8, though the genetic architecture is complex and polygenic
MAOIs
Mechanism: inhibit the enzyme monoamine oxidase, preventing breakdown of dopamine, norepinephrine, and serotonin
Result: increased monoamine availability in the synaptic cleft
Side effects: hypertensive crises (especially with tyramine-rich foods), which is why they are prescribed cautiously and usually not as a first-line treatment
TCAs
Mechanism: block reuptake of norepinephrine and serotonin at the synapse
Result: prolonged mood-enhancing neurotransmitter effects
Side effects: weight gain, sexual dysfunction, cardiotoxicity
Require careful patient monitoring due to cardiac risks
SSRIs and SNRIs
SSRIs: block serotonin reuptake only
SNRIs: block both serotonin and norepinephrine reuptake
Both increase neurotransmitter levels in the brain
Key point for exams: the therapeutic lag. These drugs change synaptic chemistry quickly, but clinical improvement takes several weeks. The reason is presynaptic autoreceptor desensitisation, which must occur before sustained neurotransmitter release increases
Brexanolone
Approved specifically for postpartum depression
Mechanism: indirect agonist of the GABA-A receptor (a different pathway from traditional monoamine-based drugs)
Notable feature: rapid action within 60 hours of administration
Ketamine
Mechanism: NMDA receptor antagonist (targets glutamate signalling, not monoamines)
Used for treatment-resistant depression
Notable feature: rapid alleviation of symptoms, in contrast to the weeks required by SSRIs/SNRIs
Electroconvulsive therapy (ECT)
Induces seizures via electrical stimulation
Appears to work by decreasing brain activity and raising the seizure threshold
Response rate: greater than 50%
Reserved for severe, treatment-resistant cases
Limitation: relapse remains a concern after treatment ends
Transcranial magnetic stimulation (TMS)
Non-invasive magnetic pulses applied to the prefrontal cortex
Alters neuronal activity to reduce depressive symptoms
Response rate: less than 30%
Advantage: minimal side effects compared to ECT
Deep brain stimulation (DBS)
Surgical implantation of electrodes in specific brain regions, particularly the subgenual anterior cingulate cortex (ACC)
Used in treatment-resistant depression
Highly targeted but invasive
Vagus nerve stimulation (VNS)
Electrical stimulation of the vagus nerve
Indirectly affects brain activity through brainstem connections
Shows promise in treatment-resistant cases
Multiple antidepressant treatments increase neurogenesis in the hippocampal dentate gyrus
The timeline of neurogenesis aligns with the weeks-long lag before antidepressants produce therapeutic effects, suggesting new neuron growth may be part of the mechanism
Stress suppresses neurogenesis; antidepressants reverse this effect (demonstrated in animal studies)
Sleep disturbances are characteristic of depression, and correcting them can improve mood
REM sleep deprivation: selective deprivation of REM sleep alleviates depressive symptoms over several weeks
Total sleep deprivation: provides rapid but temporary relief, suggesting a depressogenic substance may be produced during sleep
The therapeutic lag of SSRIs and SNRIs is why clinicians tell patients to "give it a few weeks" before judging whether a medication is working. Ketamine clinics have emerged as a real-world response to the need for faster-acting treatments in severe or treatment-resistant depression. ECT, despite its stigma, remains one of the most effective interventions available for patients who have not responded to medications.
Students often think SSRIs work slowly because they take a long time to change neurotransmitter levels. They do not. Synaptic changes are rapid; the delay is due to downstream autoreceptor desensitisation and neuronal adaptation.
Students frequently confuse MAOIs and TCAs because both are "older" antidepressants. Their mechanisms are different: MAOIs prevent neurotransmitter breakdown, while TCAs prevent neurotransmitter reuptake. These are distinct processes.
Students sometimes assume ECT is outdated or ineffective. It has a response rate above 50% in treatment-resistant depression, making it one of the most effective biological treatments available.
Students tend to overlook that ketamine works through an entirely different neurotransmitter system (glutamate/NMDA) than traditional antidepressants (monoamines). This distinction is frequently tested.
⚠️ The SSRI/SNRI therapeutic lag and its explanation (autoreceptor desensitisation) is a high-frequency exam topic. Know the mechanism, not just the fact.
⚠️ Be able to compare MAOIs, TCAs, SSRIs, and SNRIs by mechanism and side-effect profile.
⚠️ Know that brexanolone (GABA-A) and ketamine (NMDA) represent departures from the monoamine hypothesis, and be able to explain why their rapid onset is significant.
⚠️ ECT response rate (>50%) vs. TMS response rate (<30%) is a commonly tested comparison.
⚠️ The neurogenesis hypothesis: antidepressants promote hippocampal neurogenesis, and the timeline matches the therapeutic lag. This is a favourite exam question linking pharmacology to neurobiology.
True or false: SSRIs take several weeks to alter serotonin levels at the synapse. (False, synaptic changes are rapid; the clinical delay is due to autoreceptor desensitisation.)
Fill in the blank: The concordance rate for depression in monozygotic twins is approximately ____%, compared to ____% in dizygotic twins. (69%, 13%)
True or false: Ketamine works by blocking serotonin reuptake. (False, it is an NMDA receptor antagonist.)
Fill in the blank: Brexanolone is approved specifically for __________ depression and acts on the __________ receptor. (Postpartum, GABA-A)
True or false: TMS has a higher response rate than ECT. (False, TMS is under 30%, ECT is above 50%.)
Q: Explain why SSRIs take several weeks to produce therapeutic effects despite rapidly altering synaptic serotonin levels.
A: SSRIs quickly block serotonin reuptake, increasing synaptic serotonin. However, presynaptic autoreceptors initially compensate by reducing serotonin release. Therapeutic effects emerge only after these autoreceptors desensitise over several weeks, allowing sustained increases in serotonin signalling and downstream neuronal adaptations.
Q: Compare the mechanisms of MAOIs and TCAs.
A: MAOIs inhibit the enzyme monoamine oxidase, which prevents the breakdown of dopamine, norepinephrine, and serotonin in the synaptic cleft. TCAs block the reuptake transporters for norepinephrine and serotonin, preventing these neurotransmitters from being recycled back into the presynaptic neuron. Both increase monoamine availability, but through different mechanisms.
Q: Why is ketamine considered significant in the treatment of depression?
A: Ketamine is an NMDA receptor antagonist that provides rapid relief of depressive symptoms, in contrast to the weeks-long lag of traditional antidepressants. It works through the glutamate system rather than the monoamine system, offering a treatment option for patients with treatment-resistant depression who have not responded to SSRIs, SNRIs, TCAs, or MAOIs.
Q: What evidence supports a genetic basis for depression?
A: Close relatives of individuals with affective disorders are 10 times more likely to develop them. Twin studies show a 69% concordance rate in monozygotic twins compared to 13% in dizygotic twins. Specific genes such as RORA and GRM8 have been implicated, though the genetic architecture is complex and polygenic.
Q: Describe the neurogenesis hypothesis of antidepressant action.
A: Several antidepressant treatments increase neurogenesis in the hippocampal dentate gyrus. The timeline of this neurogenesis matches the weeks-long delay before antidepressants produce clinical effects. Animal studies show that stress suppresses hippocampal neurogenesis while antidepressants reverse this suppression, suggesting that new neuron growth may be a necessary component of the antidepressant response.
This material connects directly to the monoamine hypothesis of depression covered earlier in the course, as most pharmacological treatments are grounded in the idea that depression involves deficits in serotonin, norepinephrine, or dopamine signalling. The neurogenesis section links to neuroscience topics on hippocampal function and neuroplasticity. The circadian rhythms and sleep deprivation findings connect to broader work on biological rhythms and their role in mood regulation, which may appear in units on sleep disorders or chronobiology.
Depression treatment, antidepressant mechanisms, SSRI mechanism of action, SNRI mechanism, MAOI mechanism, tricyclic antidepressants, TCA side effects, serotonin reuptake, norepinephrine reuptake, monoamine hypothesis, presynaptic autoreceptor desensitisation, therapeutic lag antidepressants, brexanolone postpartum depression, GABA-A agonist, ketamine depression, NMDA antagonist, treatment-resistant depression, electroconvulsive therapy ECT, transcranial magnetic stimulation TMS, deep brain stimulation DBS, vagus nerve stimulation VNS, neurogenesis hippocampus, dentate gyrus, circadian rhythms depression, sleep deprivation depression, REM sleep deprivation, concordance rate twins, heritability depression, RORA gene, GRM8 gene, abnormal psychology, University of Florida, affective disorders